1. Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
- Author
-
Fabien Calcagno, Cristian Villanueva, Elsa Curtit, Thierry Nguyen, Erion Dobi, Xavier Pivot, François Kleinclauss, Philippe Montcuquet, Stefano Kim, and Antoine Thiery-Vuillemin
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Review ,urologic and male genital diseases ,chemotherapy ,lcsh:RC254-282 ,taxane ,Prostate cancer ,Internal medicine ,medicine ,Chemotherapy ,Taxane ,business.industry ,Cancer ,cabazitaxel ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,prostate cancer ,Clinical trial ,Docetaxel ,Cabazitaxel ,Hormonal therapy ,business ,Biomedical engineering ,medicine.drug ,castrate resistant - Abstract
Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men with castration-resistant prostate cancer (CRPC). Cabazitaxel (XRP6258, TXD258, and RPR116258A), a tubulin-binding taxane drug as potent as docetaxel in cell lines, was the first treatment able to prolong survival for metastatic CRPC in the post-docetaxel setting. This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed.
- Published
- 2012